Russell Investments Group Ltd. Lowers Position in QIAGEN N.V. $QGEN

Key Points

• Russell Investments Group Ltd. significantly decreased its stake in QIAGEN N.V. by 43.2% during the first quarter, owning approximately 0.12% of the company after selling 197,990 shares.
• Analysts have shown a mixed response, with Wall Street Zen downgrading QIAGEN from a "strong-buy" to a "buy" rating, while UBS raised its price target from $48.00 to $50.00.
• QIAGEN announced a quarterly dividend of $0.25 per share, which represents a yield of 52.0%, with a current dividend payout ratio of 14.79%.

Russell Investments Group Ltd. trimmed its holdings in QIAGEN N.V. (NYSE:QGEN - Free Report) by 43.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 260,687 shares of the company's stock after selling 197,990 shares during the quarter. Russell Investments Group Ltd. owned about 0.12% of QIAGEN worth $10,407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in QGEN. ANTIPODES PARTNERS Ltd acquired a new position in QIAGEN during the 1st quarter worth approximately $94,000. Tower Research Capital LLC TRC raised its stake in QIAGEN by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after buying an additional 2,204 shares during the period. GAMMA Investing LLC raised its stake in QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after buying an additional 1,425 shares during the period. Federated Hermes Inc. acquired a new position in QIAGEN during the 1st quarter worth approximately $150,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in QIAGEN during the 4th quarter worth approximately $202,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

QGEN has been the subject of a number of recent research reports. Cowen reissued a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Wall Street Zen lowered QIAGEN from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. UBS Group boosted their price objective on QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Barclays initiated coverage on QIAGEN in a report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Finally, Bank of America boosted their price objective on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Three investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $49.69.

QIAGEN Stock Performance

Shares of QGEN stock traded up $0.5840 during trading on Friday, hitting $49.7140. The company's stock had a trading volume of 882,883 shares, compared to its average volume of 1,336,129. The company has a market cap of $11.05 billion, a PE ratio of 29.37, a P/E/G ratio of 2.61 and a beta of 0.64. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The business has a fifty day moving average of $48.61 and a 200-day moving average of $43.90. QIAGEN N.V. has a 52 week low of $37.63 and a 52 week high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. During the same period in the prior year, the company posted $0.55 earnings per share. QIAGEN's quarterly revenue was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, research analysts anticipate that QIAGEN N.V. will post 2.26 earnings per share for the current year.

QIAGEN Dividend Announcement

The company also recently disclosed a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a dividend of $0.25 per share. This represents a yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's dividend payout ratio is 14.79%.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.